Bushby, K;
Finkel, R;
Wong, B;
Barohn, R;
Campbell, C;
Comi, GP;
Connolly, AM;
... McDonald, CM; + view all
(2014)
Ataluren treatment of patients with nonsense mutation dystrophinopathy.
Muscle and Nerve
, 50
(4)
pp. 477-487.
10.1002/mus.24332.
Preview |
Text
Quinlivan_ptpmcrender.pdf - Published Version Download (352kB) | Preview |
Abstract
Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double‐blind, placebo‐controlled study; males ≥5 years with nm‐dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N = 57); ataluren 20, 20, 40 mg/kg (N = 60); or placebo (N = 57) for 48 weeks. The primary endpoint was change in 6‐Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ = 31.3 meters, post hoc P = 0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm‐dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.
Archive Staff Only
 |
View Item |
